In 2009, the first report of new and more potent HIV-specific broadly neutralizing antibodies kicked off something of an antibody frenzy. Since then, researchers have isolated nearly two dozen broadly neutralizing antibodies from HIV-infected donors. These antibodies are vital clues for HIV vaccine development and are now being used by researchers to try to reverse engineer vaccine immunogens. In this second installment of IAVI Report’s Living History of AIDS Vaccine Research, Managing Editor Kristen Jill Kresge and Science Writer Regina McEnery turned to four experts to provide some perspective on these recent advances in antibody research and to frame the current efforts to design vaccine candidates that can induce antibodies against HIV.